CA2045950A1 - Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections - Google Patents

Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections

Info

Publication number
CA2045950A1
CA2045950A1 CA 2045950 CA2045950A CA2045950A1 CA 2045950 A1 CA2045950 A1 CA 2045950A1 CA 2045950 CA2045950 CA 2045950 CA 2045950 A CA2045950 A CA 2045950A CA 2045950 A1 CA2045950 A1 CA 2045950A1
Authority
CA
Canada
Prior art keywords
proteins
cytolytic
vaccine
prevention
pleuropneumoniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2045950
Other languages
French (fr)
Other versions
CA2045950C (en
Inventor
Elbarte M. Kamp
Marinus A. Smits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centraal Diergeneeskundig Instituut
Original Assignee
Centraal Diergeneeskundig Instituut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centraal Diergeneeskundig Instituut filed Critical Centraal Diergeneeskundig Instituut
Priority to CA 2045950 priority Critical patent/CA2045950C/en
Publication of CA2045950A1 publication Critical patent/CA2045950A1/en
Application granted granted Critical
Publication of CA2045950C publication Critical patent/CA2045950C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a vaccine for the prevention and/or the treatment of infection by Actinobacillus pleuropneumoniae, the causative agent of porcine pleuropneumonia, which vaccine contains at least an immunogenic part of at least one cytolytic protein of A. pleuropneumoniae produced by recombinant DNA, and detoxified derivatives thereof. Three of such cytolytic proteins are identified and a vaccine containing these, or parts or derivatives thereof, ensures protection against all known serotypes of A. pleuropneumoniae. The cytolytic proteins are produced by inserting a nucleotide sequence encoding one or more of the proteins or parts thereof in a host cell, cultivating the host cell and recovering the proteins.
Another vaccine contains the genetic information for one or more of the cytolytic proteins, and a passive vaccine contains antibodies against these proteins. The invention further provides monoclonal,antibodies and DNA
probes for use in diagnostics.
CA 2045950 1991-06-28 1991-06-28 Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections Expired - Fee Related CA2045950C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2045950 CA2045950C (en) 1991-06-28 1991-06-28 Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2045950 CA2045950C (en) 1991-06-28 1991-06-28 Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections

Publications (2)

Publication Number Publication Date
CA2045950A1 true CA2045950A1 (en) 1992-12-29
CA2045950C CA2045950C (en) 2004-05-11

Family

ID=4147933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2045950 Expired - Fee Related CA2045950C (en) 1991-06-28 1991-06-28 Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections

Country Status (1)

Country Link
CA (1) CA2045950C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US6019984A (en) * 1995-03-01 2000-02-01 University Of Guelph Bacterial preparations, method for producing same, and their use as vaccines
US6610307B1 (en) * 1995-11-02 2003-08-26 Commonwealth Scientific And Industrial Research Organisation Immunity against pasteurella haemolytica leukotoxin
US6770275B1 (en) * 1996-05-31 2004-08-03 Akzo Nobel N.V. Live attenuated RTC-producing bacteria of the family

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019984A (en) * 1995-03-01 2000-02-01 University Of Guelph Bacterial preparations, method for producing same, and their use as vaccines
US6610307B1 (en) * 1995-11-02 2003-08-26 Commonwealth Scientific And Industrial Research Organisation Immunity against pasteurella haemolytica leukotoxin
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US6410021B1 (en) 1995-11-30 2002-06-25 Univ Michigan State Vaccines of pasteurellaceae mutants and vaccination method
US6770275B1 (en) * 1996-05-31 2004-08-03 Akzo Nobel N.V. Live attenuated RTC-producing bacteria of the family

Also Published As

Publication number Publication date
CA2045950C (en) 2004-05-11

Similar Documents

Publication Publication Date Title
EP0874051A3 (en) OSP a protein of borrelia burgdorferi subgroups, encoding genes and vaccines.
EP1347055A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis
CA2123579A1 (en) Recombinant multivalent m protein vaccine
WO1999042588A3 (en) Group b streptococcus antigens
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
EP1275720A3 (en) Histidyl-trna synthetase of staphylococcus aureus
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU6236396A (en) Omp26 antigen from haemophilus influenzae
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
NO974969L (en) Multimeric recombinant urease vaccine
CA2105057A1 (en) Dna sequences which code for virulence characteristics of streptococcus suis and part thereof polypeptides and antibodies derived therefrom and the use thereof for the diagnosis of and protection against infection by s. suis in mammals, including man
GB9219936D0 (en) Vaccines
CA2045950A1 (en) Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections
CA2071863A1 (en) Recombinant vaccine for porcine pleuropneumonia
CA2113562A1 (en) Poultry mycoplasma antigens, gene thereof and recombinant vectors containing the gene as well as vaccines utilizing the same
AU5625796A (en) Protective epitopes of adenyl cyclase-haemolysin(AC-Hly), their application to the treatment or to the prevention of bordetella infections
CA2378862A1 (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
GR3033151T3 (en) Vaccine protecting against porcine hemophilus.
WO2000046242A3 (en) 19 KILODALTON PROTEIN OF $i(HELICOBACTER PYLORI)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed